Cardiac Safety of Esketamine Nasal Spray in Treatment-Resistant Depression: Results from the Clinical Development Program
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1179-1934
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Cardiac Safety of Esketamine Nasal Spray in Treatment-Resistant Depression: Results from the Clinical Development Program ; volume:34 ; number:3 ; day:29 ; month:1 ; year:2020 ; pages:299-310 ; date:3.2020
CNS drugs ; 34, Heft 3 (29.1.2020), 299-310, 3.2020
- Creator
-
Doherty, Teodora
Wajs, Ewa
Melkote, Rama
Miller, Janice
Singh, Jaskaran B.
Weber, Michael A.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s40263-020-00699-4
- URN
-
urn:nbn:de:101:1-2020052300110773587179
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 11:04 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Doherty, Teodora
- Wajs, Ewa
- Melkote, Rama
- Miller, Janice
- Singh, Jaskaran B.
- Weber, Michael A.
- SpringerLink (Online service)
Other Objects (12)
Management of treatment-resistant depression with esketamine nasal spray: clinical questions for daily practice in Gulf Cooperation Council countries
Efficacy and safety of esketamine nasal spray by sex in patients with treatment-resistant depression: findings from short-term randomized, controlled trials
Personalized use of ketamine and esketamine for treatment-resistant depression
Assessment of health-related quality of life and health status in patients with treatment-resistant depression treated with esketamine nasal spray plus an oral antidepressant
Effect of Esketamine Nasal Spray on Olfactory Function and Nasal Tolerability in Patients with Treatment-Resistant Depression: Results from Four Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Studies
Efficacy and Safety of Esketamine Nasal Spray in Patients with Treatment-Resistant Depression Who Completed a Second Induction Period: Analysis of the Ongoing SUSTAIN-3 Study
Cost-Utility Analysis of Esketamine for Patients with Treatment-Resistant Depression in Italy
Oral esketamine for treatment-resistant depression: rationale and design of a randomized controlled trial
Cost-utility analysis of esketamine and electroconvulsive therapy in adults with treatment-resistant depression
Correction to: Oral esketamine for treatment-resistant depression: rationale and design of a randomized controlled trial
Real-world approach to managing dysgeusia following the use of esketamine nasal spray: a case report
Use of intranasal esketamine in a girl with treatment-resistant depression and autism spectrum disorders : a case report
Management of treatment-resistant depression with esketamine nasal spray: clinical questions for daily practice in Gulf Cooperation Council countries
Efficacy and safety of esketamine nasal spray by sex in patients with treatment-resistant depression: findings from short-term randomized, controlled trials
Personalized use of ketamine and esketamine for treatment-resistant depression
Assessment of health-related quality of life and health status in patients with treatment-resistant depression treated with esketamine nasal spray plus an oral antidepressant
Effect of Esketamine Nasal Spray on Olfactory Function and Nasal Tolerability in Patients with Treatment-Resistant Depression: Results from Four Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Studies
Efficacy and Safety of Esketamine Nasal Spray in Patients with Treatment-Resistant Depression Who Completed a Second Induction Period: Analysis of the Ongoing SUSTAIN-3 Study
Cost-Utility Analysis of Esketamine for Patients with Treatment-Resistant Depression in Italy
Oral esketamine for treatment-resistant depression: rationale and design of a randomized controlled trial
Cost-utility analysis of esketamine and electroconvulsive therapy in adults with treatment-resistant depression
Correction to: Oral esketamine for treatment-resistant depression: rationale and design of a randomized controlled trial
Real-world approach to managing dysgeusia following the use of esketamine nasal spray: a case report
Use of intranasal esketamine in a girl with treatment-resistant depression and autism spectrum disorders : a case report
Management of treatment-resistant depression with esketamine nasal spray: clinical questions for daily practice in Gulf Cooperation Council countries
Efficacy and safety of esketamine nasal spray by sex in patients with treatment-resistant depression: findings from short-term randomized, controlled trials
Personalized use of ketamine and esketamine for treatment-resistant depression
Assessment of health-related quality of life and health status in patients with treatment-resistant depression treated with esketamine nasal spray plus an oral antidepressant
Effect of Esketamine Nasal Spray on Olfactory Function and Nasal Tolerability in Patients with Treatment-Resistant Depression: Results from Four Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Studies
Efficacy and Safety of Esketamine Nasal Spray in Patients with Treatment-Resistant Depression Who Completed a Second Induction Period: Analysis of the Ongoing SUSTAIN-3 Study
Cost-Utility Analysis of Esketamine for Patients with Treatment-Resistant Depression in Italy
Oral esketamine for treatment-resistant depression: rationale and design of a randomized controlled trial
Cost-utility analysis of esketamine and electroconvulsive therapy in adults with treatment-resistant depression
Correction to: Oral esketamine for treatment-resistant depression: rationale and design of a randomized controlled trial
Real-world approach to managing dysgeusia following the use of esketamine nasal spray: a case report